{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:02:40Z","timestamp":1784876560018,"version":"3.55.0"},"reference-count":22,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2026.2962","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:35:20Z","timestamp":1782300920000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Advanced pulmonary carcinoid managed with chemoimmunotherapy and antiangiogenic agent: A case report and literature review"],"prefix":"10.3892","volume":"25","author":[{"given":"Liqiu","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Oncology, Tumor Hospital of Mudanjiang, Mudanjiang, Heilongjiang 157009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tumor Hospital of Mudanjiang, Mudanjiang, Heilongjiang 157009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"520","key":"key20260724093423_b1-MCO-25-2-02962","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030520","article-title":"Bronchial carcinoids: From molecular background to treatment approach","volume":"14","author":"Araujo-Castro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260724093423_b2-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"key20260724093423_b3-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/COC.0000000000000221","article-title":"Primary pulmonary carcinoid tumor: A Long-term single institution experience","volume":"41","author":"Herde","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"key20260724093423_b4-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00292-024-01360-3","article-title":"Diagnostic issues in neuroendocrine neoplasms of the lung","volume":"45","author":"Kasajima","year":"2024","journal-title":"Pathologie (Heidelb)"},{"key":"key20260724093423_b5-MCO-25-2-02962","first-page":"1537","article-title":"Primary carcinoid tumors of the lung: A role for radiotherapy","volume":"20","author":"Mackley","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"key20260724093423_b6-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260724093423_b7-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lungcan.2015.08.018","article-title":"Systemic therapy for pulmonary carcinoids","volume":"90","author":"Marquez-Medina","year":"2015","journal-title":"Lung Cancer"},{"key":"key20260724093423_b8-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/ITT.S494670","article-title":"Immune checkpoint inhibitor combined with antiangiogenic agent synergistically improving the treatment efficacy for solid tumors","volume":"13","author":"Zhou","year":"2024","journal-title":"Immunotargets Ther"},{"issue":"106556","key":"key20260724093423_b9-MCO-25-2-02962","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106556","article-title":"Induction of immunogenic cell death by novel platinum-based anticancer agents","volume":"187","author":"Chang","year":"2023","journal-title":"Pharmacol Res"},{"key":"key20260724093423_b10-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3779\/j.issn.1009-3419.2016.12.07","article-title":"Expression and clinical significance of PD-1 and PD-L1 in pulmonary carcinoids","volume":"19","author":"Li","year":"2016","journal-title":"Chin J Lung Cancer"},{"key":"key20260724093423_b11-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20260724093423_b12-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in Extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260724093423_b13-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20260724093423_b14-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","article-title":"Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: A nonrandomized clinical trial","volume":"8","author":"Halperin","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20260724093423_b15-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1158\/1078-0432.CCR-22-1552","article-title":"A Phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms","volume":"29","author":"Owen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20260724093423_b16-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-023-10952-w","article-title":"Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: A multicenter retrospective cohort study","volume":"23","author":"Song","year":"2023","journal-title":"BMC Cancer"},{"key":"key20260724093423_b17-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/s-0045-1809341","article-title":"Pediatric theranostics in a 13-Year-Old female with bronchial carcinoid","volume":"24","author":"Trpezanovski","year":"2025","journal-title":"World J Nucl Med"},{"issue":"100750","key":"key20260724093423_b18-MCO-25-2-02962","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100750","article-title":"First report of response to tarlatamab in a patient with DLL3-Positive pulmonary carcinoid: Case report","volume":"5","author":"Cooper","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"key20260724093423_b19-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.21037\/tlcr-24-352","article-title":"A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement","volume":"13","author":"Hu","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"key20260724093423_b20-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12055-024-01858-8","article-title":"Contralateral metachronous pulmonary carcinoid tumor 7 years after lobectomy","volume":"41","author":"\u00c7a\u011fan","year":"2025","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"key20260724093423_b21-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.aace.2024.08.002","article-title":"Severe ectopic adrenocorticotropic hormone syndrome due to pulmonary carcinoid tumor: A case report and literature review","volume":"10","author":"Aldrete","year":"2024","journal-title":"AACE Clin Case Rep"},{"key":"key20260724093423_b22-MCO-25-2-02962","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s42000-021-00316-z","article-title":"Cushing's syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: A case report and literature review","volume":"21","author":"Bostan","year":"2022","journal-title":"Hormones (Athens)"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:34:27Z","timestamp":1784874867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2026.2962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,24]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2026.2962","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}